Giuseppe Saglio Selected Research

BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

10/2022	Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
6/2022	Dihydroorotate dehydrogenase inhibition reveals metabolic vulnerability in chronic myeloid leukemia.
12/2021	Shedding Light on Targeting Chronic Myeloid Leukemia Stem Cells.
10/2021	Droplet Digital PCR for BCR-ABL1 Monitoring in Diagnostic Routine: Ready to Start?
7/2021	Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
3/2021	Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Venetoclax-Loaded Immunoliposome.
1/2021	Genetic Screening for Potential New Targets in Chronic Myeloid Leukemia Based on Drosophila Transgenic for Human BCR-ABL1.
1/2021	Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial.
1/2021	Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.
1/2021	Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Giuseppe Saglio Research Topics

Disease

142	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 10/2022 - 02/2002
34	Neoplasms (Cancer) 02/2022 - 07/2002
32	Philadelphia Chromosome 01/2021 - 02/2002
23	Leukemia 12/2019 - 06/2002
20	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/2021 - 02/2002
15	Blast Crisis (Blast Phase) 01/2020 - 03/2003
14	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 11/2016 - 09/2003
11	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2022 - 01/2004
6	Residual Neoplasm 10/2021 - 02/2002
5	Iron Overload 01/2020 - 01/2010
5	Hematologic Neoplasms (Hematological Malignancy) 11/2017 - 09/2007
5	Multiple Myeloma 05/2017 - 01/2006
5	Chromosome Aberrations (Chromosome Abnormalities) 04/2015 - 05/2002
4	Inflammation (Inflammations) 01/2022 - 09/2007
4	Primary Myelofibrosis (Myelosclerosis) 01/2021 - 02/2014
4	Pleural Effusion (Pleural Effusions) 01/2018 - 04/2015
3	Disease Progression 01/2021 - 05/2002
3	Myeloid Leukemia (Leukemia, Myelocytic) 01/2020 - 12/2009
3	Myeloproliferative Disorders (Myeloproliferative Disorder) 03/2014 - 06/2007
2	Lymphoma (Lymphomas) 01/2021 - 06/2020
2	Aplastic Anemia (Anemia, Hypoplastic) 01/2020 - 11/2017
2	Systemic Mastocytosis 08/2019 - 01/2018
2	Wilms Tumor (Wilm's Tumor) 01/2016 - 04/2003
2	Anemia 01/2016 - 04/2010
2	Thrombosis (Thrombus) 09/2015 - 02/2014
2	Genomic Instability 04/2015 - 01/2015
2	Carcinogenesis 01/2015 - 09/2007
2	Iron Deficiencies 06/2014 - 09/2012
2	Headache (Headaches) 09/2011 - 06/2010
2	Exanthema (Rash) 09/2011 - 02/2008
2	Hypereosinophilic Syndrome (Loeffler Endocarditis) 05/2009 - 09/2007
2	Pathologic Complete Response 02/2009 - 12/2008
1	Infections 01/2022
1	COVID-19 08/2021
1	Pneumonia (Pneumonitis) 08/2021
1	Mitochondrial Diseases (Mitochondrial Disease) 10/2020
1	Hematologic Diseases (Blood Diseases) 12/2019

Drug/Important Bio-Agent (IBA)

94	Imatinib Mesylate (Gleevec)FDA Link 07/2021 - 02/2002
52	Tyrosine Kinase InhibitorsIBA 06/2022 - 03/2004
30	nilotinib FDA Link 10/2022 - 02/2008
25	Proteins (Proteins, Gene)FDA Link 01/2022 - 05/2002
21	Dasatinib (BMS 354825)FDA Link 01/2020 - 11/2006
11	bcr-abl Fusion ProteinsIBA 08/2017 - 02/2002
10	Phosphotransferases (Kinase)IBA 12/2020 - 06/2005
9	IronIBA 10/2020 - 01/2010
8	Messenger RNA (mRNA)IBA 10/2021 - 05/2002
8	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2021 - 12/2004
8	Biological ProductsIBA 12/2020 - 09/2003
8	Interferon-alpha (Interferon Alfa)IBA 08/2010 - 03/2002
6	Pharmaceutical PreparationsIBA 01/2020 - 09/2007
5	CalreticulinIBA 01/2021 - 01/2016
5	Protein Isoforms (Isoforms)IBA 11/2016 - 03/2006
4	EnzymesIBA 02/2021 - 02/2013
4	InterferonsIBA 12/2020 - 03/2003
4	Deferasirox FDA Link 10/2020 - 02/2008
4	Biomarkers (Surrogate Marker)IBA 08/2017 - 02/2009
4	AntigensIBA 08/2017 - 01/2008
4	NF-kappa B (NF-kB)IBA 10/2016 - 09/2007
3	Dihydroorotate DehydrogenaseIBA 06/2022 - 01/2021
3	DNA (Deoxyribonucleic Acid)IBA 02/2022 - 12/2008
3	ruxolitinibIBA 08/2021 - 02/2014
3	Indicators and Reagents (Reagents)IBA 01/2021 - 11/2010
3	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2017 - 03/2003
3	HepcidinsIBA 01/2016 - 04/2010
3	Transferrin Receptors (Transferrin Receptor)IBA 01/2016 - 04/2010
3	NucleophosminIBA 03/2008 - 01/2005
2	pyrimidineIBA 02/2021 - 01/2021
2	ElementsIBA 06/2020 - 12/2019
2	Oncogene Proteins (Oncogene Protein)IBA 01/2019 - 02/2006
2	Monoclonal AntibodiesIBA 08/2017 - 05/2017
2	Transcription Factors (Transcription Factor)IBA 10/2016 - 10/2003
2	Genetic Markers (Genetic Marker)IBA 06/2015 - 01/2004
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2015 - 09/2011
2	Amino Acids FDA Link 05/2012 - 06/2011
2	Thalidomide (Thalomid)FDA Link 01/2011 - 01/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 08/2010 - 02/2004
2	Valproic Acid (Depakote)FDA LinkGeneric 03/2006 - 07/2005
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 01/2022
1	Janus Kinase InhibitorsIBA 08/2021
1	venetoclaxIBA 03/2021
1	Dipyridamole (Persantine)FDA LinkGeneric 02/2021
1	diphenyl (biphenyl)IBA 01/2021
1	pyridineIBA 01/2021
1	ponatinibIBA 01/2021
1	Immunoglobulin G (IgG)IBA 01/2021
1	LigandsIBA 12/2020
1	Activin Receptors (Activin Receptor)IBA 12/2020
1	ferrous sulfate FDA Link 01/2020
1	eltrombopag FDA Link 01/2020
1	midostaurinIBA 08/2019
1	HematinicsIBA 01/2019

Therapy/Procedure

56	Therapeutics 02/2022 - 02/2002
5	Drug Therapy (Chemotherapy) 07/2019 - 12/2007
4	Stem Cell Transplantation 10/2015 - 12/2008
3	Immunotherapy 12/2018 - 06/2007
2	Chelation Therapy (Therapy, Chelation) 11/2017 - 01/2010
2	Aftercare (After-Treatment) 05/2016 - 01/2004
2	Molecular Targeted Therapy 01/2015 - 06/2010
1	Complementary Therapies (Alternative Medicine) 12/2020
1	Homologous Transplantation 12/2020